E
ProMIS Neurosciences, Inc. PMN
$14.61 $0.322.24% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$14.29
Volume
2
Avg Vol (90D)
121,980
Market Cap
$30.76M
Dividend & Yield
--
52-Week Range
$6.27 - $39.75
P/E (TTM)
--
EPS (TTM)
-$18.70
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Insider Buying: Promis Neurosciences (NASDAQ:PMN) Major Shareholder Acquires 700,741 Shares of Stock
2/6/2026 - MarketBeat
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2/4/2026 - Globe Newswire
ProMIS Neurosciences Shares Jump 9% On $175 Mln PIPE Financing
1/30/2026 - RTT News - Momentum Stocks
Promis Neurosciences Inc trading resumes
1/30/2026 - TipRanks Financial Blog
Promis Neurosciences Inc trading resumes
1/30/2026 - The Fly
Promis Neurosciences Inc trading resumes
1/30/2026 - The Fly
Promis Neurosciences Inc trading halted, volatility trading pause
1/30/2026 - TipRanks Financial Blog
Promis Neurosciences Inc trading halted, volatility trading pause
1/30/2026 - The Fly
ProMIS Neurosciences Secures $175 Mln In Private Financing
1/30/2026 - Nasdaq News: Markets
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
1/30/2026 - Globe Newswire
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzheimer's Trial
12/18/2025 - GuruFocus
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ...
12/18/2025 - GuruFocus
ProMIS Neurosciences exceeds target enrollment in PRECISE-AD
12/18/2025 - TipRanks Financial Blog
ProMIS Neurosciences exceeds target enrollment in PRECISE-AD
12/18/2025 - The Fly
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
12/18/2025 - Globe Newswire
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
12/18/2025 - Globe Newswire
ProMIS Neurosciences (PMN) Reveals Promising Study Results for Alzheimer's Treatment
12/10/2025 - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting ...
12/10/2025 - GuruFocus
ProMIS Neurosciences announces publication highlighting PMN310
12/10/2025 - The Fly
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
12/10/2025 - Globe Newswire
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06
12/6/2025 - Nasdaq News: Stocks
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. Wainwright
12/1/2025 - GuruFocus
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright
12/1/2025 - The Fly
ProMIS Neurosciences (PMN) Presents Key Insights in Alzheimer's Research
12/1/2025 - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a ...
12/1/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$2.50M
EBIT (TTM)
-$31.90M
Net Income (TTM)
-$29.28M
Balance Sheet
Total Assets (Q)
$21.46M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$12.27M
Book Value Per Share (Q)
$4.27
Cash Flow
Cash from Operations (TTM)
-$27.55M
Cash from Investing (TTM)
-$700.00
Cash from Financing (TTM)
$21.41M
Net Change in Cash (TTM)
-$6.14M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
End of March (est)
Price History
Loading...
Beta
1.61
7-Day Total Return
3.99%
30-Day Total Return
98.37%
60-Day Total Return
49.73%
90-Day Total Return
24.82%
Year to Date Total Return
104.77%
1-Year Total Return
-35.07%
2-Year Total Return
-71.90%
3-Year Total Return
-88.30%
5-Year Total Return
-92.51%
52-week Low
Nov 28, 2025 - $6.27
52-week High
Jul 21, 2025 - $39.75
Valuation
Market Cap
$30.76M - Nano Cap
Enterprise Value
$15.33M
Price/Sales (TTM)
--
Price/Book (Q)
3.35
Dividends and Shares
Shares Outstanding
1.95M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.promisneurosciences.com
Phone Number
416 847 6898
Address
1920 Yonge Street
Toronto, ON M4S 3E2
Country
Canada
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s... more
NASDAQ 02/11/2026 4:00PM Eastern Quotes delayed